Search Results
Your search for The ASCO matches 21144 pages
Showing 16851 - 16900Expert Point of View: Nasser H. Hanna, MD
In an accompanying editorial, Nasser H. Hanna, MD, of Indiana University, Indianapolis, suggested that although the question of two chemotherapy drugs vs one in this setting made sense at the time GOIRC 02-2006 was initiated, advances in understanding of the heterogeneity of non–small cell lung...
Bendamustine/Rituximab Noninferior to Standard Chemotherapy for Advanced Indolent Non-Hodgkin and Mantle Cell Lymphomas
The combination of bendamustine (Treanda) and rituximab (Rituxan), or BR, was found to be noninferior to commonly used chemotherapy with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) or R-CVP (rituximab plus cyclophosphamide, vincristine, and prednisone) in...
Obesity, Physical Inactivity Linked with Risk for Subtype of Colorectal Cancer
An increasing body mass index (BMI) was associated with a higher risk for colorectal cancer with a specific molecular characteristic, and inversely, physical activity was linked to a decreased risk for that same cancer, according to data published in Cancer Research,1 a journal of the American...
Apogenix Receives FDA Orphan Drug Designation for APG101 to Treat Myelodysplastic Syndromes and Initiates Clinical Phase I Study
Apogenix GmbH, a biopharmaceutical company developing novel protein therapeutics for the treatment of cancer and inflammatory diseases, announced that its lead compound, APG101 (Apocept), has been granted orphan drug designation from the FDA for the treatment of myelodysplastic syndromes (MDS)....
Ibrutinib Receives Two Oncology Breakthrough Therapy Designations from FDA
Janssen Research & Development, LLC, and Pharmacyclics, LLC, announced that the FDA has granted Breakthrough Therapy Designations for the investigational oral agent ibrutinib as a monotherapy for two B-cell malignancies: in patients with relapsed or refractory mantle cell lymphoma who have...
Targeted Therapy Gaining Ground in the Second-line Treatment of Gastric Cancer
In gastric cancer, the concept of targeted therapy assumed clinical significance when the addition of trastuzumab (Herceptin) to chemotherapy improved survival by almost 3 months in the ToGA trial.1 Another anti-HER2 agent, lapatinib (Tykerb), now looks promising, as does an agent targeting the...
T-DM1 for HER2-positive Metastatic Breast Cancer Receives FDA Approval
The FDA approved the antibodydrug conjugate ado-trastuzumab emtansine (Kadcyla), referred to as T-DM1 during clinical research, for patients with HER2-positive, metastatic breast cancer who were previously treated with trastuzumab (Herceptin) and taxane chemotherapy. Ado-trastuzumab emtansine was...
Building CancerLinQ: The Road to Faster, More Efficient Treatment Delivery
In June, Clifford A. Hudis, MD, Chief of the Breast Cancer Medicine Service and Attending Physician at Memorial Sloan-Kettering Cancer Center, and Professor in the Department of Medicine at Weill Cornell Medical College, will begin his term as President of ASCO. Among Dr. Hudis’ priorities will be...
Number of Cancer Survivors Expected to Increase to 18 Million by 2022
The American Association for Cancer Research recently released its second Annual Report on Cancer Survivorship in the United States. The report shows that as of January 2012, there were approximately 13.7 million cancer survivors in the United States, a number that is expected to rise by 31% to 18...
Flaxseed
Dietary supplement use by patients with cancer has increased significantly over the past 2 decades despite insufficient evidence of safety and effectiveness. Finding reliable sources of information about dietary supplements can be daunting. Patients typically rely on family, friends, and the...
Barrie R. Cassileth, MS, PhD, Champion of Integrative Oncology, Continues to Nurture Growth of the Field
Over the past decade, integrative oncology has gained wide acceptance as an evidenced-based way to improve the lives of patients with cancer throughout the continuum of their care. The ASCO Post recently spoke with Barrie R. Cassileth, MS, PhD, Chief of the Integrative Medicine Service and Laurance ...
Disclosure: Appropriate or Not?
The ASCO Post is an outstanding publication that I always look forward to reading. I also understand there are policies and rules to be followed, particularly regarding conflicts of interest and disclosures from contributors. I am writing in regard to “Cancer Has Made Me A Better Doctor,” by David...
Conflicts of Interest
In looking at a recent issue of The ASCO Post, I noted that expert opinions from specialists were published alongside a number of clinical reports. Below each opinion was a disclosure statement, often saying that the expert had no conflict of interest to report. While I do not know each of these...
Another Perspective on Accountable Care Organizations
I read with great interest Dr. Richard Boxer’s editorial on accountable care organizations in the January 15 issue of The ASCO Post. Much of what he says is unfortunately true. There are several points that I would like to make, however. First of all, Dr. Boxer states that the “principle that...
Alex's Lemonade Stand Foundation Introduces Centers of Excellence Program to Further Childhood Cancer Research
Alex’s Lemonade Stand Foundation (ALSF), a registered 501(c)(3) charity, is furthering its commitment to finding cures for all children with cancer by introducing the ALSF Centers of Excellence program. The Centers of Excellence program aims to fund the research of leading childhood cancer...
Focus on the Louisiana Oncology Society
Founded on September 1, 1992, by John M. Rainey, MD, the Louisiana Oncology Society has had numerous legislative successes (see sidebar) since that time, including leading the effort to support Louisiana’s Oral Chemotherapy Parity Law, which was passed in 2012 and is now in effect throughout the...
Ramon Parsons, MD, PhD, Named Chair of Oncological Sciences at the Icahn School of Medicine at Mount Sinai
Renowned scientist Ramon E. Parsons, MD, PhD, has been named Chair of the Department of Oncological Sciences at the Icahn School of Medicine at Mount Sinai, New York. Dr. Parsons is a researcher in cancer genetics and will bring an interdisciplinary, holistic approach to Mount Sinai’s research...
SIDEBAR: Expect Questions from Your Patients
Recently reported data from the Prostate Cancer Outcome Study (PCOS) can “serve as a tool for a medical oncologist, a urologic oncologist, or a radiation oncologist to say, ‘Here is what could happen on average at 2, 5, 15 years after treatment with either surgery or radiation,’” according to the...
Recently Reported Long-term Outcomes Could Motivate More Men with Prostate Cancer to Consider Active Surveillance
Fifteen years after being treated with radical prostatectomy or external-beam radiation for localized prostate cancer, “the prevalence of erectile dysfunction was nearly universal,” among men enrolled in a long-term functional outcomes analysis of the Prostate Cancer Outcomes Study (PCOS). There...
Radiation, Still Misunderstood after All These Years
Over the past few decades, radiation therapies have rapidly advanced, due, in large part, to an increasing technologic armamentarium. Among modern science’s most impressive machines, for example, 220-ton particle accelerators can generate near-light-speed beams of protons, with sniper-like...
New Vice President of Indiana Cancer Services
Holly Goe, RN, MSN, has been named Vice President of Indiana University Health Cancer Centers, Indianapolis. She has been serving as interim Vice President since October after being named the program’s Executive Director for Clinical Operations last April. Before joining IU Health in April 2012,...
Majority of Ovarian Cancer Patients Do Not Receive Recommended Treatment, Study Shows
Women are 30% less likely to die of ovarian cancer if they have guideline-recommended treatment, yet nearly two-thirds of those with the disease do not receive it, often because they are cared for at hospitals that treat a small number of ovarian cancer patients. These are the findings of a study...
Intraperitoneal Chemotherapy Gives Ovarian Cancer Patients Better Chance of Survival
Patients with advanced ovarian cancer who undergo intensive treatment with chemotherapy that bathes the abdomen are significantly more likely to live longer than those who receive standard intravenous (IV) chemotherapy, according to a study that analyzed long-term follow-up from two landmark...
Oncology Meetings
April IV Latin American Symposium of Gastroenterology OncologyApril 17-20 • Vina del Mar, ChileFor more information: www.slago.com 3rd ITLT Essen 2013 - Interdisciplinary Treatment of Liver TumorsApril 18-20 • Essen, GermanyFor more information: www.itlt.org The Arizona Clinical Oncology Society...
Three-marker Assay for Early Detection of Renal Cancer
Early detection of renal cell carcinoma using biomarkers remains challenging. Kim and colleagues recently evaluated a three-marker assay consisting of nicotinamide N-methyltransferase (NNMT), L-plastin (LCP1), and nonmetastatic cells 1 protein (NM23A). After validation of the three-marker assay in...
Mixed-lineage Kinase 4 Interacts with Activated RAS Signaling in Colorectal Cancer
Colorectal cancer that is microsatellite stable but chromosomally unstable is characterized by poor prognosis and remains largely intractable at the metastatic stage. Mutational analysis has shown that the mixed lineage kinase 4 (MLK4) protein kinase is frequently mutated in microsatellite-stable...
Effects of siRNA Combining TGF-β1 Silencing and RIG-I Activation in Pancreas Cancer
Dysregulation of TGF-β signaling promotes tumor growth, invasion, metastasis, and a potent immunosuppressive network in pancreas cancer. A strategy for disrupting the tumor-promoting pathway is the silencing of TGF-β by use of small-interfering (si) RNA. Ellermeier and colleagues found that the...
Jonathan Friedberg, MD, Named Director of the James P. Wilmot Cancer Center
Jonathan Friedberg, MD, MMSc, has been appointed Director of the James P. Wilmot Cancer Center at the University of Rochester Medical Center in New York. Dr. Friedberg joined the Medical Center in 2002 and was named Chief of the Division of Hematology/Oncology in the Department of Medicine in 2009. ...
New ACCC Officers and Trustees
Results of the election of new officers and trustees (2013–2014) for the Association of Community Cancer Centers (ACCC) were announced recently at the ACCC Annual National Meeting. First Nonphysician ACCC President Elected Virginia Vaitones, MSW, became ACCC President at the 39th Annual National...
NCI Guide Helps Providers Get Adolescent and Young Adult Patients Involved in End-of-life Care
Enabling adolescent and young adult (AYA) patients to become involved in advance care planning can help parents and health-care agents make informed decisions, alleviate distress, and possibly improve the patients’ quality of life, according to researchers at the National Cancer Institute’s...
Implementing a National Cancer Clinical Trials System for the 21st Century
In March 2011, the National Cancer Policy Forum of the Institute of Medicine (IOM), in conjunction with ASCO, held a workshop to discuss a collaborative approach to making the National Cancer Institute (NCI)-funded clinical trials system more viable and productive. That workshop included...
SIDEBAR: Patient Advocate Scholarship Program
The Conquer Cancer Foundation’s Patient Advocate Scholarship Program enables advocates to attend ASCO meetings so they may further educate themselves on important advances in their areas of interest. The scholarship program is one of many programs ASCO and the Conquer Cancer Foundation provide for...
The Future of Clinical Guidelines in Oncology
Clinical guidelines, like those of ASCO and the National Comprehensive Cancer Network (NCCN), clearly have represented the standard of care and, to a large extent, the basis for coverage policy, especially in the area of medical oncology. However, guidelines increasingly seem to be in the shadow of ...
Dual Awards Pay Tribute to Gender Equity Trailblazers
The University of Texas MD Anderson Cancer Center in Houston recently recognized two leading advocates for women in medicine and research. Karen Antman, MD, Provost of the Boston University Medical Campus and Dean of its School of Medicine since 2005, was the recipient of the 2013 Margaret L....
Indiana University Researchers Earn $3.2 Million Grant to Develop, Improve Therapies for Pancreatic Cancer
Two Indiana University researchers have been awarded a multiyear, $3.2 million grant to develop and improve therapies for pancreatic cancer, the fourth leading cause of cancer death in the United States. Mark R. Kelley, PhD, Betty and Earl Herr Professor of Pediatric Oncology Research, and Melissa...
New Partnership Will Harness Technology to Foster Improved Palliative Care in Oncology
ASCO and the American Academy of Hospice and Palliative Care Medicine (AAHPM) have announced a joint initiative to support delivery of high-quality palliative care in medical oncology. The initiative, funded by the Agency for Health Care Research & Quality, aims to address the complex care...
Managing Side Effects: Urinary Incontinence
Cancer.Net recently added an article on urinary incontinence to help patients learn how to cope with this side effect. In the article, patients can learn about the causes of urinary incontinence and how it is diagnosed, as well as read about the treatment options and how it can be managed. To learn ...
ASCO Develops New Physician Payment Reform Webpage and Four-part Educational Series
To help keep its members and the cancer community apprised and educated on the issue of payment reform, ASCO has developed a payment reform webpage and issued an ASCO in Action educational series. This four-part series is designed to help ASCO members better understand the complex issue of...
Conquer Cancer Foundation Arms Patients with Knowledge through patientACCESS
Receiving a cancer diagnosis can be a frightening and overwhelming experience, and the first thing many people do upon receiving the news is seek out information, hoping to be empowered through knowledge. At the Conquer Cancer Foundation, we are working to ensure that vital information—focusing on...
ASCO’s State Oncology Societies Booth Provides a Place for Relationship Building and Sharing Best Practices
Want to learn how to best lobby your local state legislators on the issues that affect your practice in your state? Or finally meet the executive director of your state’s oncology society? Look for the State Oncology Societies Booth at ASCO’s Annual Meeting this year. The booth will be located in...
ASCO Leadership Development Program Participants 'Give Back' by Supporting the Conquer Cancer Foundation
In the fast-paced world of oncology, where the science of patient care is constantly evolving, it is critical for practitioners—and, by extension, their Society—to consistently be one step ahead. For ASCO and the Conquer Cancer Foundation, that means maintaining a strong focus not only on the...
ASCO-SEP®, 3rd Edition, Features Digital Formats and Complementary Study Tools
ASCO has released the latest edition of ASCO-SEP®, a comprehensive resource designed to help medical providers assess and improve their level of knowledge in the various areas of oncology, enabling them to provide care that will optimize the quality of life for people with cancer. ASCO-SEP, 3rd...
Gene Transfer Therapy Is Producing Prolonged Remissions in Patients with Advanced Leukemia
In August 2011, researchers from the University of Pennsylvania published their breakthrough findings of a pilot study showing sustained remissions of up to 1 year in a small number of patients with advanced chronic lymphocytic leukemia (CLL) who had been treated with genetically engineered...
American Association for Cancer Research Inaugurates the First Class of Fellows of the AACR Academy
The American Association for Cancer Research (AACR) inaugurated the first class of Fellows of the AACR Academy at the association’s annual meeting held this month in Washington, DC. The AACR Academy has been created to recognize and honor distinguished scientists whose major scientific...
NCCN Adds Two New Member Institutions
The National Comprehensive Cancer Network (NCCN) recently announced the addition of two new NCCN Member Institutions: UC San Diego Moores Cancer Center in La Jolla, California, and the University of Colorado Cancer Center in Aurora, Colorado. “We are extremely pleased that UC San Diego Moores...
SIDEBAR: Samuel M. Silver, MD, PhD, Elected Chairman of NCCN Board of Directors
Samuel M. Silver, MD, PhD, of the University of Michigan Comprehensive Cancer Center, has been elected Chairman of the National Comprehensive Cancer Network (NCCN) Board of Directors. Dr. Silver was previously Vice Chairman of the Board and succeeds Thomas A. D’Amico, MD, of the Duke Cancer...
New NCCN Guidelines for Patients Available for Adolescents and Young Adults with Cancer
The National Comprehensive Cancer Network (NCCN), with support from the NCCN Foundation and the LIVESTRONG Foundation and through collaboration with Critical Mass: The Young Adult Cancer Alliance (Critical Mass), recently announced the availability of the NCCN Guidelines for Patients: Caring for...
New Data Reported on Melanoma, Cutaneous T-cell Lymphoma, Basal Cell Carcinoma, and Cancer Treatment Side Effects
At the recent American Academy of Dermatology 71st Annual Meeting in Miami Beach, researchers presented interesting findings regarding melanoma and other skin cancers. The ASCO Post brings you the following news briefs on these topics. Melanoma Incidence Decreases among Adolescents and Children An...
Genomic Analysis of Squamous Cell Lung Cancer Tumors May Lead to More Targeted Therapies
Last fall, a consortium of more than 300 researchers from The Cancer Genome Atlas (TCGA) Research Network published the results of their large-scale genetic analysis of squamous cell lung cancer in the journal Nature.1 The study, the first of its kind, compared the tumor cells from 178 untreated...
Philips Receives FDA 510(k) Clearance for MicroDose SI Mammography System
Royal Philips Electronics recently announced that it has received 510(k) clearance from the FDA for its MicroDose SI system, a full-field digital mammography system that has the capability to enable future single-shot spectral imaging applications. High Breast Density High breast density is a known ...
